Clinician support key to patient adoption of VR therapies, study suggests

by JMIR Publications

edited by Gaby Clark, reviewed by Andrew Zinin

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

proofread

The GIST Add as preferred source

A new study published in JMIR XR and Spatial Computing demonstrates that the way virtual reality therapeutics (VRx) are introduced to patients is a critical factor in how successfully they adopt the technology. The randomized feasibility pilot study builds on growing evidence that virtual reality digital therapeutics show strong clinical potential for managing symptoms such as anxiety, pain and distress. Rather than evaluating clinical efficacy, the study focuses on a critical implementation question: how structured onboarding and provider involvement can help drive consistent patient engagement, adherence and adoption of VRx in real-world care.

While previous digital therapeutic research has focused primarily on clinical efficacy, this study experimentally isolated the onboarding process to evaluate how different implementation strategies affect early technology acceptance, usability and protocol fidelity.

The onboarding experiment

The research team evaluated 31 adult participants with limited prior virtual reality experience across three distinct implementation environments:

• Unguided use: Participants received the VR headset preloaded with the therapeutic application and minimal instructions.
• Self-directed support: Participants received the headset alongside asynchronous physical materials, quick-start guides, an in-app tutorial and access to a troubleshooting chatbot.
• Provider-led support: Participants received the self-directed materials combined with a brief, scripted five-minute consultation with a trained provider who conducted a simulated prescription, safety screening, device fitting and guided initial setup.

Key findings include:

• Increased adherence: Participants who received provider-supported onboarding demonstrated significantly greater time-based adherence ($P = .04$) and longer overall duration of engagement with the VRx intervention compared with the unguided group.
• Improved technology acceptance: Across all groups, brief exposure to the VR therapy led to statistically significant improvements in overall technology acceptance ($P < .001$), though scores remained moderate, indicating that early perceptions shift quickly but require ongoing reinforcement.
• Favorable usability: The provider-supported group demonstrated the most favorable usability pattern, including fewer observed errors and higher usability ratings. Observational data showed that human-guided setup reduced early frustration and apprehension compared with relying on self-directed physical or digital materials alone.
• High tolerability: The intervention was well tolerated across all cohorts, with low reported levels of cybersickness and no study discontinuations because of adverse effects.

"Virtual reality therapeutics are often talked about in terms of clinical outcomes, but real-world adoption depends on much more than whether the technology works. In this pilot study, even a brief provider-supported onboarding interaction appeared to make a difference in how participants engaged with VRx, how confident they felt and how closely they followed the intended use," said lead author Ashlyn Zebrowski, Ph.D.

"To scale digital therapeutics and new technologies in routine care, we have to think beyond the intervention itself. We need to better define the roles of providers and patients and design the pathway for how these tools are introduced, supported and integrated into the clinical workflow and the patients' day-to-day lives."

The qualitative findings contextualized these metrics, revealing that brief provider involvement established clinical legitimacy and set clear expectations, which directly altered how participants engaged with the technology.

More information

Ashlyn Zebrowski et al, Evaluating the Effects of Clinician Prescribing and Implementation Materials on Adoption of Virtual Reality Therapeutics: Randomized Feasibility Pilot Study, JMIR XR and Spatial Computing (2026). DOI: 10.2196/90626

Clinical categories

Allied healthPsychology & Mental health Provided by JMIR Publications Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Clinician support key to patient adoption of VR therapies, study suggests (2026, July 7) retrieved 8 July 2026 from https://medicalxpress.com/news/2026-07-clinician-key-patient-vr-therapies.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.